OncoMatch/Clinical Trials/NCT06711705
Elranatamab in Relapsed/Refractory Multiple Myeloma
Is NCT06711705 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Elranatamab for multiple myeloma.
Treatment: Elranatamab — This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD38 monoclonal antibody
including anti-CD38 monoclonal antibody
Must have received: proteasome inhibitor
including ... proteosome inhibitor (PI)
Must have received: immunomodulatory drug
including ... immunomodulatory drug (IMiD)
Cannot have received: autologous stem cell transplant
Exception: within 100 days prior to study enrollment
History of autologous stem cell transplant within 100 days prior to study enrollment
Cannot have received: allogeneic transplant
Exception: within 1 year prior to study enrollment or active graft versus host disease
History of allogeneic transplant within 1 year prior to study enrollment or active graft versus host disease
Cannot have received: investigational drug
Exception: within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Lab requirements
Blood counts
ANC ≥1,000/mm3 (G-CSF not permitted for at least 1 week prior to the first dose of elranatamab); Hemoglobin ≥8.0 g/dL (transfusion support is permitted if completed at least 1 week prior to planned start of dosing); Platelet count ≥75,000/mm3 or ≥50,000/mm3 if >50% involvement with plasma cells in the screening bone marrow (transfusion support is permitted if completed at least 1 week prior to planned start of dosing)
Kidney function
estimated creatinine clearance (CrCl) ≥30 mL/min as calculated using Cockcroft-Gault equation
Liver function
AST and ALT ≤2.5 x ULN; ≤5.0 x ULN if there is liver involvement by the tumor. Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in case of bone metastasis). Total bilirubin ≤2.0 mg/dL, except in patients with Gilbert Syndrome who must have a total bilirubin less than 3.0 mg/dL.
Adequate hematological function defined as ... Adequate renal function with estimated creatinine clearance (CrCl) ≥30 mL/min ... Adequate liver function defined as ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Diego · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify